Pharmaceutical Development of AAV-Based Gene Therapy Products for the Eye
Open accessThe DOI matches its Crossref record; 121 of the 122 references it cites were found in a registry or an index.
Abstract
A resurgence of interest and investment in the field of gene therapy, driven in large part by advances in viral vector technology, has recently culminated in United States Food and Drug Administration approval of the first gene therapy product targeting a disease caused by mutations in a single gene. This product, LUXTURNA™ (voretigene neparvovec-rzyl; Spark Therapeutics, Inc., Philadelphia, PA), delivers a normal copy of the RPE65 gene to retinal cells for the treatment of biallelic RPE65 mutation–associated retinal dystrophy, a blinding disease. Many additional gene therapy programs targeting both inherited retinal diseases and other ocular diseases are in development, owing to an improved understanding of the genetic basis of ocular disease and the unique properties of the ocular compartment that make it amenable to local gene therapy. Here we review the growing body of literature that describes both the design and development of ocular gene therapy products, with a particular emphasis on target and vector selection, and chemistry, manufacturing, and controls.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“AAV vectors offer a high number of tissue-specific serotypes, including retina-specific serotypes AAV1, 2 (Luxturna), 4, 5, 6, 7, 8, and 9,64”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [64]
In the citing paper
“Serotypes may also influence which cell types are transduced, for example, all the retina-specific serotypes are known to transduce RPE, their ability to transduce photoreceptors varies by AAV.64”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [64]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815 · cited 1×
“For example, inactivation of the 3′ long terminal repeat generates self-inactivating vectors (48).”
BackgroundFritsche, L. G., Igl, W., Bailey, J. N. C., Grassmann, F., Sengupta, S., Bragg-Gresham, J. L., Burdon, K. P., Hebbring, S. J., Wen, C., Gorski, M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3448 · Cited by 1,544 · cited 1×
“Genome-wide association studies have led to the identification of single-nucleotide polymorphisms (SNPs) associated with increased or decreased incidence of the disease (26).”
BackgroundDunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808 · cited 1×
“gion, 30–60% of humans have neutralizing antibodies to AAV2, which have the potential to inhibit cell transduction (63).”
BackgroundMacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796 · cited 1×
“With the clinical success for LCA2 patients, vector-based gene transfer is now being explored clinically for other forms of hereditary retinal diseases, including choroideremia (15),”
Non Viral Vectors in Gene Therapy- An Overview
Ramamoorth, M. (2015) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2015/10443.5394 · Cited by 761
Engineering adeno-associated viruses for clinical gene therapy
Kotterman, M. A., & Schaffer, D. V. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3742 · Cited by 761 · cited 1×
“knowledge of structure/function relationships to modify the virus capsid structure, for example by introducing mutations to reduce proteasomal degradation or to eliminate antibodybinding epitopes, or by incorporating new ligands as a means to redirect vector tropism (71).”
BackgroundLong-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414221 · Cited by 743 · cited 1×
“and functional gain following an initial peak seen at 6– 12 months after the treatment (12,13).”
BackgroundInfluentialDalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734 · cited 1×
“7m8 variant which, following intravitreal injection, is capable of efficient gene delivery to all retina layers in both mice and primates (75).”
BackgroundParks, R. J., Chen, L., Anton, M., Sankar, U., Rudnicki, M. A., & Graham, F. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13565 · Cited by 725
Jacobson, S. G. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.298 · Cited by 639
Retinitis Pigmentosa: Genes and Disease Mechanisms
Parmeggiani, F., S. Sorrentino, F., Ponzin, D., Barbaro, V., Ferrari, S., & Di Iorio, E. (2011) · Current Genomics · doi:10.2174/138920211795860107 · Cited by 627 · cited 1×
“dence of one in 3000–7000 individuals (25).”
Genes and mutations causing retinitis pigmentosa
Daiger, S. P., Sullivan, L. S., & Bowne, S. J. (2013) · Clinical Genetics · doi:10.1111/cge.12203 · Cited by 619 · cited 1×
“niques including, most recently, next-generation sequencing (17,21).”
Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802866105 · Cited by 558 · cited 2×
“This in turn leads to enhanced nuclear transport and increased transgene expression (72).”
BackgroundSimonelli, F., Maguire, A. M., Testa, F., Pierce, E. A., Mingozzi, F., Bennicelli, J. L., Rossi, S., Marshall, K., Banfi, S., Surace, E. M., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.277 · Cited by 553
New recombinant serotypes of AAV vectors
Gao, G., Vandenberghe, L., & Wilson, J. (2005) · Current Gene Therapy · doi:10.2174/1566523054065057 · Cited by 487 · cited 1×
“rAAV2, the first serotype to be successfully used for gene transfer, efficiently transduces RPE and retinal ganglion cells but is less efficient in transducing photoreceptors (47,60,61).”
BackgroundProtein Stability During Freezing: Separation of Stresses and Mechanisms of Protein Stabilization
Bhatnagar, B. S., Bogner, R. H., & Pikal, M. J. (2007) · Pharmaceutical Development and Technology · doi:10.1080/10837450701481157 · Cited by 482
Effective gene therapy with nonintegrating lentiviral vectors
Yáñez-Muñoz, R. J., Balaggan, K. S., MacNeil, A., Howe, S. J., Schmidt, M., Smith, A. J., Buch, P., MacLaren, R. E., Anderson, P. N., Barker, S. E., et al. (2006) · Nature Medicine · doi:10.1038/nm1365 · Cited by 460 · cited 1×
“Additionally, nonintegrating vectors have been developed and shown to facilitate efficient sustained transgene expression in RPE for 8 weeks in a rodent model (49).”
BackgroundStone, E. M., Andorf, J. L., Whitmore, S. S., DeLuca, A. P., Giacalone, J. C., Streb, L. M., Braun, T. A., Mullins, R. F., Scheetz, T. E., Sheffield, V. C., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.04.008 · Cited by 460
Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus
Flannery, J. G., Zolotukhin, S., Vaquero, M. I., LaVail, M. M., Muzyczka, N., & Hauswirth, W. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6916 · Cited by 407 · cited 1×
“(64,80), while cone photoreceptor–specific expression can be achieved using cone arrestin, blue opsin, or red/green opsin”
BackgroundAuricchio, A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.26.3075 · Cited by 403 · cited 2×
“Lentiviruses can effectively transduce RPE cells but not photoreceptors (46,47).”
BackgroundHigh-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors
Petrs-Silva, H., Dinculescu, A., Li, Q., Min, S.-H., Chiodo, V., Pang, J.-J., Zhong, L., Zolotukhin, S., Srivastava, A., Lewin, A. S., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.269 · Cited by 398
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
Bennett, J., Ashtari, M., Wellman, J., Marshall, K. A., Cyckowski, L. L., Chung, D. C., McCague, S., Pierce, E. A., Chen, Y., Bennicelli, J. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002865 · Cited by 395
Improvement and Decline in Vision with Gene Therapy in Childhood Blindness
Jacobson, S. G., Cideciyan, A. V., Roman, A. J., Sumaroka, A., Schwartz, S. B., Heon, E., & Hauswirth, W. W. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412965 · Cited by 372 · cited 1×
“and functional gain following an initial peak seen at 6– 12 months after the treatment (12,13).”
BackgroundInfluentialBourges, J.-L., Gautier, S. E., Delie, F., Bejjani, R. A., Jeanny, J.-C., Gurny, R., BenEzra, D., & Behar-Cohen, F. F. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-1068 · Cited by 357 · cited 1×
“Additionally, in vivo experiments have established that PLA nanoparticles are well tolerated and can cross the retina following intravitreal administration, with a preferential localization to RPE cells (44).”
BackgroundInner limiting membrane barriers to aav-mediated retinal transduction from the vitreous
Dalkara, D., Kolstad, K. D., Caporale, N., Visel, M., Klimczak, R. R., Schaffer, D. V., & Flannery, J. G. (2009) · Molecular Therapy · doi:10.1038/mt.2009.181 · Cited by 357
Campochiaro, P. A., Nguyen, Q. D., Shah, S. M., Klein, M. L., Holz, E., Frank, R. N., Saperstein, D. A., Gupta, A., Stout, J. T., Macko, J., et al. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.167 · Cited by 343 · cited 1×
“derived factor for neovascular AMD demonstrated safety and some evidence of a sustained therapeutic effect (52).”
BackgroundTesta, F., Maguire, A. M., Rossi, S., Pierce, E. A., Melillo, P., Marshall, K., Banfi, S., Surace, E. M., Sun, J., Acerra, C., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.11.048 · Cited by 330
Cideciyan, A. V., Hauswirth, W. W., Aleman, T. S., Kaushal, S., Schwartz, S. B., Boye, S. L., Windsor, E. A. M., Conlon, T. J., Sumaroka, A., Pang, J.-J., et al. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.086 · Cited by 312
Correction of the retinal dystrophy phenotype of the RCS rat by viral gene transfer of Mertk
Vollrath, D., Feng, W., Duncan, J. L., Yasumura, D., D'Cruz, P. M., Chappelow, A., Matthes, M. T., Kay, M. A., & LaVail, M. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.221364198 · Cited by 290 · cited 1×
“Both the tyrosine-protein kinase Mer and RPE65 have been expressed in RPE using Ad5 delivered subretinally and were shown to rescue function in animal models (50,51).”
MethodManufacturing of recombinant adeno-associated viral vectors for clinical trials
Clément, N., & Grieger, J. C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.2 · Cited by 286 · cited 1×
“Clinical preparations of AAV2 have been produced with heparin affinity chromatography using elution at elevated ionic strength (94,95).”
MethodDoroudchi, M. M., Greenberg, K. P., Liu, J., Silka, K. A., Boyden, E. S., Lockridge, J. A., Arman, A. C., Janani, R., Boye, S. E., Boye, S. L., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.69 · Cited by 277
Bennicelli, J., Wright, J. F., Komaromy, A., Jacobs, J. B., Hauck, B., Zelenaia, O., Mingozzi, F., Hui, D., Chung, D., Rex, T. S., et al. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300389 · Cited by 267 · cited 2×
“(105) under the terms of the CC BY-NC-ND 4.”
BackgroundGene therapy for red–green colour blindness in adult primates
Mancuso, K., Hauswirth, W. W., Li, Q., Connor, T. B., Kuchenbecker, J. A., Mauck, M. C., Neitz, J., & Neitz, M. (2009) · Nature · doi:10.1038/nature08401 · Cited by 265
A comprehensive review of retinal gene therapy
Boye, S. E., Boye, S. L., Lewin, A. S., & Hauswirth, W. W. (2013) · Molecular Therapy · doi:10.1038/mt.2012.280 · Cited by 262 · cited 1×
“AAV has emerged as the predominant vector for ocular gene therapy (6).”
BackgroundBeltran, W. A., Cideciyan, A. V., Lewin, A. S., Iwabe, S., Khanna, H., Sumaroka, A., Chiodo, V. A., Fajardo, D. S., Román, A. J., Deng, W.-T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118847109 · Cited by 260 · cited 1×
“ing protein promoters can drive expression of transgenes in both cone and rod photoreceptors (78,79).”
BackgroundNovel adeno-associated virus serotypes efficiently transduce murine photoreceptors
Allocca, M., Mussolino, C., Garcia-Hoyos, M., Sanges, D., Iodice, C., Petrillo, M., Vandenberghe, L. H., Wilson, J. M., Marigo, V., Surace, E. M., et al. (2007) · Journal of Virology · doi:10.1128/jvi.01327-07 · Cited by 246 · cited 1×
“(64,80), while cone photoreceptor–specific expression can be achieved using cone arrestin, blue opsin, or red/green opsin”
BackgroundDosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey
Vandenberghe, L. H., Bell, P., Maguire, A. M., Cearley, C. N., Xiao, R., Calcedo, R., Wang, L., Castle, M. J., Maguire, A. C., Grant, R., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002103 · Cited by 242 · cited 1×
“rAAV2, the first serotype to be successfully used for gene transfer, efficiently transduces RPE and retinal ganglion cells but is less efficient in transducing photoreceptors (47,60,61).”
BackgroundBiology and therapy of inherited retinal degenerative disease: insights from mouse models
Veleri, S., Lazar, C. H., Chang, B., Sieving, P. A., Banin, E., & Swaroop, A. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.017913 · Cited by 231 · cited 1×
“to assess potential therapeutics, including gene therapy approaches (23).”
BackgroundQuantification of adeno-associated virus particles and empty capsids by optical density measurement
Sommer, J. Ü. M., Smith, P. H., Parthasarathy, S., Isaacs, J., Vijay, S., Kieran, J., Powell, S. K., McClelland, A., & Wright, J. F. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(02)00019-9 · Cited by 230 · cited 1×
“(122) further showed that ultraviolet absorbance of denatured”
BackgroundHeier, J. S., Kherani, S., Desai, S., Dugel, P., Kaushal, S., Cheng, S. H., Delacono, C., Purvis, A., Richards, S., Le-Halpere, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30979-0 · Cited by 229
Venkatakrishnan, B., Yarbrough, J., Domsic, J., Bennett, A., Bothner, B., Kozyreva, O. G., Samulski, R. J., Muzyczka, N., McKenna, R., & Agbandje-McKenna, M. (2013) · Journal of Virology · doi:10.1128/jvi.02524-12 · Cited by 225 · cited 4×
“02524-12 (102) with permission from American Society for Microbiology.”
BackgroundMethodInfluentialWright, J. (2014) · Biomedicines · doi:10.3390/biomedicines2010080 · Cited by 219 · cited 4×
“serum- or other animal-derived products in the cell culture media, nucleic acids from host cells, and, in the case of AAV, non-transfected plasmid (90).”
BackgroundInfluentialRestoration of cone vision in a mouse model of achromatopsia
Alexander, J. J., Umino, Y., Everhart, D., Chang, B., Min, S. H., Li, Q., Timmers, A. M., Hawes, N. L., Pang, J.-J., Barlow, R. B., et al. (2007) · Nature Medicine · doi:10.1038/nm1596 · Cited by 218
Gene therapy rescues cone function in congenital achromatopsia
Komáromy, A. M., Alexander, J. J., Rowlan, J. S., Garcia, M. M., Chiodo, V. A., Kaya, A., Tanaka, J. C., Acland, G. M., Hauswirth, W. W., & Aguirre, G. D. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq136 · Cited by 217
Kong, J., Kim, S.-R., Binley, K., Pata, I., Doi, K., Mannik, J., Zernant-Rajang, J., Kan, O., Iqball, S., Naylor, S., et al. (2008) · Gene Therapy · doi:10.1038/gt.2008.78 · Cited by 215 · cited 1×
“Lentiviruses can effectively transduce RPE cells but not photoreceptors (46,47).”
BackgroundKlimczak, R. R., Koerber, J. T., Dalkara, D., Flannery, J. G., & Schaffer, D. V. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007467 · Cited by 210 · cited 1×
“an AAV6 variant, has increased tropism for glial cells following intravitreal delivery and has been shown to rescue retinal function in a rat model of RP (76,77).”
BackgroundNovel AAV serotypes for improved ocular gene transfer
Lebherz, C., Maguire, A., Tang, W., Bennett, J., & Wilson, J. M. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1126 · Cited by 208
Yang, G. S., Schmidt, M., Yan, Z., Lindbloom, J. D., Harding, T. C., Donahue, B. A., Engelhardt, J. F., Kotin, R., & Davidson, B. L. (2002) · Journal of Virology · doi:10.1128/jvi.76.15.7651-7660.2002 · Cited by 204
Weber, M., Rabinowitz, J., Provost, N., Conrath, H., Folliot, S., Briot, D., Chérel, Y., Chenuaud, P., Samulski, J., Moullier, P., et al. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00098-4 · Cited by 203
Macé, E., Caplette, R., Marre, O., Sengupta, A., Chaffiol, A., Barbe, P., Desrosiers, M., Bamberg, E., Sahel, J.-A., Picaud, S., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.154 · Cited by 197
Development of formulations that enhance physical stability of viral vectors for gene therapy
Croyle, M., Cheng, X., & Wilson, J. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301527 · Cited by 188
Michalakis, S., Mühlfriedel, R., Tanimoto, N., Krishnamoorthy, V., Koch, S., Fischer, M. D., Becirovic, E., Bai, L., Huber, G., Beck, S. C., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.149 · Cited by 185
Vector platforms for gene therapy of inherited retinopathies
Trapani, I., Puppo, A., & Auricchio, A. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.08.001 · Cited by 183 · cited 6×
“tial downside of the use of adenovirus is that it can induce immune responses that can limit transgene expression, even in the subretinal space (45).”
BackgroundInfluentialVascular endothelial growth factor biology: clinical implications for ocular treatments
Bhisitkul, R. B. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.098426 · Cited by 181 · cited 1×
“In the case of neovascular AMD, the role of VEGF as a principal mediator of neovascularization is well established, a fact underscored by the success of antiVEGF therapies in treating the disease (28).”
BackgroundNanoparticles for gene delivery to retinal pigment epithelial cells.
Bejjani, R. A., BenEzra, D., Cohen, H., Rieger, J., Andrieu‐Soler, C., Jeanny, J., Gollomb, G., & Béhar‐Cohen, F. (2005) · PubMed · Cited by 176
Carvalho, L. S., Xu, J., Pearson, R. A., Smith, A. J., Bainbridge, J. W., Morris, L. M., Fliesler, S. J., Ding, X.-Q., & Ali, R. R. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr218 · Cited by 173
Qu, G., Bahr-Davidson, J., Prado, J., Tai, A., Cataniag, F., McDonnell, J., Zhou, J.-M., Hauck, B., Luna, J., Sommer, J. M., et al. (2006) · Journal of Virological Methods · doi:10.1016/j.jviromet.2006.11.019 · Cited by 163 · cited 1×
“More recently, anion exchange chromatography has been shown to be able to separate full and empty capsids based on differences in electrical charge between the two particles due to the presence or absence of the viral genome (97).”
BackgroundMartino, A. T., Basner-Tschakarjan, E., Markusic, D. M., Finn, J. D., Hinderer, C., Zhou, S., Ostrov, D. A., Srivastava, A., Ertl, H. C. J., Terhorst, C., et al. (2013) · Blood · doi:10.1182/blood-2012-10-460733 · Cited by 162 · cited 1×
“Additionally, these mutations have the potential to reduce major histocompatibility complex class 1 presentation of capsid antigens because of reduced proteasomal degradation of proteins (74).”
BackgroundThermal Stability as a Determinant of AAV Serotype Identity
Bennett, A., Patel, S., Mietzsch, M., Jose, A., Lins-Austin, B., Yu, J. C., Bothner, B., McKenna, R., & Agbandje-McKenna, M. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.07.003 · Cited by 159 · cited 2×
“(124) suggested the application of DSF to determine melting temperatures for AAV serotype identification (Fig.”
BackgroundWright, J. F., Le, T., Prado, J., Bahr-Davidson, J., Smith, P. H., Zhen, Z., Sommer, J. M., Pierce, G. F., & Qu, G. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.02.021 · Cited by 158 · cited 8×
“can mediate virus aggregation (93), presumably by bridging between cationic virions, and this effect is reduced by nuclease digestion.”
BackgroundInfluentialAge-related macular degeneration: genome-wide association studies to translation
Black, J. R., & Clark, S. J. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.70 · Cited by 157 · cited 10×
“AAV Adeno-associated virus AMD Age-related macular degeneration CD Circular dichroism CMC Chemistry, manufacturing, and controls DP Drug product DS Drug substance DSC Differential scanning calorimetry DSF Differential scanning fluorimetry FDA United States Food and Drug Administration GMP Good manufacturing practice H…”
BackgroundInfluentialProduction, purification and characterization of adeno-associated vectors
Ayuso, E., Mingozzi, F., & Bosch, F. (2010) · Current Gene Therapy · doi:10.2174/156652310793797685 · Cited by 151
Universal Method for the Purification of Recombinant AAV Vectors of Differing Serotypes
Nass, S. A., Mattingly, M. A., Woodcock, D. A., Burnham, B. L., Ardinger, J. A., Osmond, S. E., Frederick, A. M., Scaria, A., Cheng, S. H., & O’Riordan, C. R. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.12.004 · Cited by 146 · cited 1×
“A wide range of AAV serotypes have been shown to be capable of affinity purification using AVB-Sepharose High Performance (GEHealthcare; Chicago, IL) (96), an adsorbent that is functionalized with single-domain antibody fragments that bind a commonly occurring epitope on the outer surface of the AAV capsid with high s…”
MethodVitreous Is a Barrier in Nonviral Gene Transfer by Cationic Lipids and Polymers
Pitkänen, L., Ruponen, M., Nieminen, J., & Urtti, A. (2003) · Pharmaceutical Research · doi:10.1023/a:1023238530504 · Cited by 134 · cited 1×
“Howeve r , polyethyleneimine-based polymers have not shown efficient delivery to the retina following intravitreal injection (42).”
BackgroundBhatnagar, B. S., Pikal, M. J., & Bogner, R. H. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21017 · Cited by 124
Singh, S. K., Kolhe, P., Mehta, A., Chico, S., Lary, A. L., & Huang, M. Z. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0343-z · Cited by 122
Genetic variants in the complement system predisposing to age-related macular degeneration: A review
Schramm, E. C., Clark, S. J., Triebwasser, M. P., Raychaudhuri, S., Seddon, J. M., & Atkinson, J. P. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.06.032 · Cited by 121 · cited 1×
“Many of the SNPs occur in genes encoding components of the complement pathway (27).”
BackgroundDalkara, D., Kolstad, K. D., Guerin, K. I., Hoffmann, N., Visel, M., Klimczak, R. R., Schaffer, D. V., & Flannery, J. G. (2011) · Molecular Therapy · doi:10.1038/mt.2011.62 · Cited by 121 · cited 1×
“an AAV6 variant, has increased tropism for glial cells following intravitreal delivery and has been shown to rescue retinal function in a rat model of RP (76,77).”
BackgroundAnalysis of the VMD2 Promoter and Implication of E-box Binding Factors in Its Regulation
Esumi, N., Oshima, Y., Li, Y., Campochiaro, P. A., & Zack, D. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309881200 · Cited by 116 · cited 1×
“Similarly, RPE-specific expression has been demonstrated using the RPE65 or VMD2 promoter (84,85), and specific expression can be achieved in ON-”
BackgroundProtein Formulation and Delivery
(2007) · CRC Press eBooks · doi:10.3109/9780849379529 · Cited by 110
Pincock, R. E. (1969) · Accounts of Chemical Research · doi:10.1021/ar50016a001 · Cited by 110
Lotery, A. J., Yang, G. S., Mullins, R. F., Russell, S. R., Schmidt, M., Stone, E. M., Lindbloom, J. D., Chiorini, J. A., Kotin, R. M., & Davidson, B. L. (2003) · Human Gene Therapy · doi:10.1089/104303403322542301 · Cited by 107
Immune Responses Limit Adenovirally Mediated Gene Expression in the Adult Mouse Eye
Reichel, M., Ali, R., Thrasher, A., Hunt, D., Bhattacharya, S., & Baker, D. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300691 · Cited by 106 · cited 1×
“Cytotoxic T-cells have been shown to remove transduced cells expressing adenovirus proteins (53).”
BackgroundKhan, A. O. (2011) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e32834922d2 · Cited by 103 · cited 1×
“For example, in glaucoma, many of the underlying genetic causes of hereditary forms of the disease have been identified (19), and causal genetic mutations have Ta bl e I (c on ti nu ed )”
BackgroundAAV-mediated photoreceptor transduction of the pig cone-enriched retina
Mussolino, C., della Corte, M., Rossi, S., Viola, F., Di Vicino, U., Marrocco, E., Neglia, S., Doria, M., Testa, F., Giovannoni, R., et al. (2011) · Gene Therapy · doi:10.1038/gt.2011.3 · Cited by 102
Takahashi, K., Igarashi, T., Miyake, K., Kobayashi, M., Yaguchi, C., Iijima, O., Yamazaki, Y., Katakai, Y., Miyake, N., Kameya, S., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.008 · Cited by 99
Delgado, D., del Pozo‐Rodríguez, A., Solinís, M. Á., Avilés-Triqueros, M., Weber, B. H. F., Fernández, E., & Rodríguez‐Gascón, A. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.115 · Cited by 97 · cited 1×
“Subretinal injections of solid lipid nanoparticles have resulted in transfection of RPE cells in vivo (41).”
BackgroundToward an elucidation of the molecular genetics of inherited retinal degenerations
Farrar, G. J., Carrigan, M., Dockery, A., Millington-Ward, S., Palfi, A., Chadderton, N., Humphries, M., Kiang, A. S., Kenna, P. F., & Humphries, P. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx185 · Cited by 94 · cited 1×
“In particular, understanding of the genetics of inherited retinal diseases (IRDs) has grown dramatically (17).”
BackgroundEghrari, A. O., Riazuddin, S. A., & Gottsch, J. D. (2015) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2015.04.005 · Cited by 93 · cited 1×
“been identified in multiple genes associated with Fuchs corneal dystrophy (20).”
BackgroundNon-viral ocular gene therapy: Potential ocular therapeutic avenues
Bloquel, C., Bourges, J., Touchard, E., Berdugo, M., BenEzra, D., & Béhar‐Cohen, F. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.023 · Cited by 93 · cited 3×
“conjunctival epithelium is inefficient, limiting the utility of this approach for anterior segment diseases (31).”
BackgroundInfluentialGerometta, R. M. D. R., Spiga, M., Borrás, T., & Candia, O. A. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-4920 · Cited by 93 · cited 1×
“talloproteinase gene into cells of the trabecular meshwork to control intraocular pressure in an animal model (34).”
BackgroundEnhanced Real-Time Monitoring of Adeno-Associated Virus Trafficking by Virus–Quantum Dot Conjugates
Joo, K., Fang, Y. H., Liu, Y., Liang, X., Gu, Z., Tai, A., Lee, C.-L., Tang, Y., & Wang, P. (2011) · ACS Nano · doi:10.1021/nn102651p · Cited by 92
Schwegman, J. J., Carpenter, J. F., & Nail, S. L. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21843 · Cited by 90
D'Costa, S., Blouin, V., Broucque, F., Penaud-Budloo, M., Fçranois, A., Perez, I. C., Le Bec, C., Moullier, P., Snyder, R. O., & Ayuso, E. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.19 · Cited by 89
Treatment of ocular disorders by gene therapy
Solinís, M. Á., del Pozo-Rodríguez, A., Apaolaza, P. S., & Rodríguez-Gascón, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.022 · Cited by 88 · cited 2×
“core, and ranging in size from 50 to 1000 nm (16), are another vehicle that is being explored.”
BackgroundRecombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector.
Jf, W., Qu, G., Tang, C., & Sommer, J. M. (2003) · PubMed · Cited by 81
RPE65 Gene Delivery Restores Isomerohydrolase Activity and Prevents Early Cone Loss in Rpe65−/−Mice
Chen, Y., Moiseyev, G., Takahashi, Y., & Ma, J.-X. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0965 · Cited by 80 · cited 1×
“Both the tyrosine-protein kinase Mer and RPE65 have been expressed in RPE using Ad5 delivered subretinally and were shown to rescue function in animal models (50,51).”
MethodKachi, S., Oshima, Y., Esumi, N., Kachi, M., Rogers, B. S., Zack, D. J., & Campochiaro, P. A. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302475 · Cited by 80 · cited 1×
“can mediate uptake into RPE cells following subretinal injection (40).”
BackgroundRetinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications
Schön, C., Biel, M., & Michalakis, S. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.01.009 · Cited by 77 · cited 1×
“the use of strong ubiquitous promoters such as the cytomegalovirus or the chimeric chicken β-actin/cytomegalovirus enhancer/promoter (55).”
BackgroundSchnödt, M., & Büning, H. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.188 · Cited by 77
Constable, I. J., Lai, C.-M., Magno, A. L., French, M. A., Barone, S. B., Schwartz, S. D., Blumenkranz, M. S., Degli-Esposti, M. A., & Rakoczy, E. P. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.02.018 · Cited by 76
Kinetics of reactions in frozen solutions
Pincock, R. E., & Kiovsky, T. E. (1966) · Journal of Chemical Education · doi:10.1021/ed043p358 · Cited by 73
Enhanced Kinetics of Pseudo First-Order Hydrolysis in Liquid Phase Coexistent with Ice
Anzo, K., Harada, M., & Okada, T. (2013) · The Journal of Physical Chemistry A · doi:10.1021/jp409126p · Cited by 68
Targeting gene expression to cones with human cone opsin promoters in recombinant AAV
Komáromy, A. M., Alexander, J. J., Cooper, A. E., Chiodo, V. A., Acland, G. M., Hauswirth, W. W., & Aguirre, G. K. (2008) · Gene Therapy · doi:10.1038/gt.2008.32 · Cited by 66
Naldini, L. (2009) · Science · doi:10.1126/science.1181937 · Cited by 63
Peden, M. C., Min, J., Meyers, C., Lukowski, Z., Li, Q., Boye, S. L., Levine, M., Hauswirth, W. W., Ratnakaram, R., Dawson, W., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017140 · Cited by 63
Viral receptors and vector purification: New approaches for generating clinical-grade reagents
Summerford, C., & Samulski, R. J. (1999) · Nature Medicine · doi:10.1038/8470 · Cited by 58 · cited 1×
“Clinical preparations of AAV2 have been produced with heparin affinity chromatography using elution at elevated ionic strength (94,95).”
MethodLarge-scale production, purification and crystallization of wild-type adeno-associated virus-2
Xie, Q., Hare, J. T., Turnigan, J., & Chapman, M. S. (2004) · Journal of Virological Methods · doi:10.1016/j.jviromet.2004.07.007 · Cited by 58 · cited 5×
“5%, below the critical micelle concentration) reduced aggregation (103).”
BackgroundInfluentialPseudotyped AAV vectors for constitutive and regulated gene expression in the eye
Auricchio, A. (2003) · Vision Research · doi:10.1016/s0042-6989(02)00676-4 · Cited by 57 · cited 1×
“exchange of capsids between different serotypes resulting in hybrid or “pseudotyped” AAV vectors (62).”
BackgroundCheng, H.-C., Yeh, S., Tsao, Y., & Kuo, P. (2007) · PubMed · Cited by 54
Stability of proteins at subzero temperatures: thermodynamics and some ecological consequences
Franks, F., & Hatley, R. H. M. (1991) · Pure and Applied Chemistry · doi:10.1351/pac199163101367 · Cited by 52
Young, J. E., Vogt, T., Gross, K. W., & Khani, S. C. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.03-0197 · Cited by 47 · cited 1×
“ing protein promoters can drive expression of transgenes in both cone and rod photoreceptors (78,79).”
BackgroundCombined Rod and Cone Transduction by Adeno-Associated Virus 2/8
Manfredi, A., Marrocco, E., Puppo, A., Cesi, G., Sommella, A., Corte, M. D., Rossi, S., Giunti, M., Craft, C. M., Bacci, M. L., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.154 · Cited by 47
Assaying the Stability and Inactivation of AAV Serotype 1 Vectors
Howard, D. B., & Harvey, B. K. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.180 · Cited by 46
(1998) · PubMed · Cited by 42
Aartsen, W. M., van Cleef, K. W. R., Pellissier, L. P., Hoek, R. M., Vos, R. M., Blits, B., Ehlert, E. M. E., Balaggan, K. S., Ali, R. R., Verhaagen, J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012387 · Cited by 41
Engineering AAV receptor footprints for gene therapy
Madigan, V. J., & Asokan, A. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.05.001 · Cited by 40 · cited 1×
“The three capsid proteins contain a common β-barrel domain but different Nterminal extensions (59).”
BackgroundManufacturing and Regulatory Strategies for Clinical AAV2-hRPE65
Fraser Wright, J., Wellman, J., & High, K. (2010) · Current Gene Therapy · doi:10.2174/156652310793180715 · Cited by 36 · cited 1×
“Another product-related concern arises from the possibility that the cell line may harbor adventitious agents that accumulate with the AAV product (91).”
BackgroundEnzymic and Acid Hydrolysis of Sucrose as Influenced by Freezing
Lund, D. B., Fennema, O. R., & Powrie, W. D. (1969) · Journal of Food Science · doi:10.1111/j.1365-2621.1969.tb10370.x · Cited by 35
Establishment of two quantitative nested qPCR assays targeting the human EPO transgene
Neuberger, E. W. I., Perez, I. C., Guiner, C. L., Moser, D., Ehlert, T., Allais, M., Moullier, P., Simon, P. D., & Snyder, R. O. (2016) · Gene Therapy · doi:10.1038/gt.2016.2 · Cited by 34 · cited 1×
“(121) described the use of quantitative polymerase chain reaction and its advantages for quantification of AAV.”
BackgroundYoon, K. C., Bae, J. A., Park, H. J., Im, S., Oh, H. J., Lin, X. H., Kim, M. Y., Lee, J. H., Lee, S. E., Ahn, K. Y., et al. (2009) · Gene Therapy · doi:10.1038/gt.2009.50 · Cited by 30 · cited 1×
“However, viral delivery does not have these same limitations, as subconjunctival injections of AAV expressing antiangiogenics have shown efficacy in inhibiting corneal neovascularization in animal models (32,33).”
BackgroundBruewer, A. R., Mowat, F. M., Bartoe, J. T., Boye, S. L., Hauswirth, W. W., & Petersen-Jones, S. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060218 · Cited by 29 · cited 1×
“the spread of virus beyond the bleb formed at the injection site is limited (37), in most cases this is acceptable if the bleb is in”
BackgroundSolid-Liquid state diagrams in pharmaceutical lyophilisation: Crystallization of solutes
Shalaev, E., & Franks, F. (2002) · Royal Society of Chemistry eBooks · doi:10.1039/9781847550118-00200 · Cited by 27
Self-citationAdvance Understanding of Buffer Behavior during Lyophilization
Wu, C., Shamblin, S. L., Varshney, D. B., & Shalaev, E. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2383-0_3 · Cited by 22 · cited 1×
“It should be noted that AAV freeze-thaw stability can be impacted by freeze-induced pH changes; the pH changes depend on the type and concentration of buffer and the presence of other excipients (100).”
BackgroundSelf-citationRational Choice of Excipients for Use in Lyophilized Formulations
Shalaev, E., Wang, W., & Gatlin, L. A. (2007) · CRC Press eBooks · doi:10.3109/9780849379529-12 · Cited by 15 · cited 1×
“A typical biological DP contains several excipients, including a buffer, lyo/cryo protector, tonicity agent, and surfactant (98,99).”
BackgroundSelf-citationWang, P., Li, H., Yang, H., Wang, H. B., Lu, J., Zhang, Y., & Hu, J. (2007) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2007.06.027 · Cited by 5 · cited 1×
“(3%) was found to be sufficient to eliminate AAV aggregation on a solid surface (104).”
Background
Research works printed but not linked: 2
- Singh S, Kolhe P, Wang W, Nema S. Large-scale freezing of biologics. Bioprocess Int. 2009;7(9):32–44.
- Sommer J, Sanftner L, Feng L, Suzuki B, Zhen Z, Powell S, et al. Optimal recovery of AAV-AADC vector from Teflon catheters using Polysorbate 80 or Pluronic F68 (abstract 768). Mol Ther. 2002;5(Suppl):S251.
Cited by
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
The approved gene therapy drugs worldwide: from 1998 to 2019
Ma, C.-C., Wang, Z.-L., Xu, T., He, Z.-Y., & Wei, Y.-Q. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107502 · Cited by 310
Manufacturing challenges and rational formulation development for AAV viral vectors
Srivastava, A., Mallela, K. M. G., Deorkar, N., & Brophy, G. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.03.024 · Cited by 269
Gene editing and CRISPR in the clinic: current and future perspectives
Hirakawa, M. P., Krishnakumar, R., Timlin, J. A., Carney, J. P., & Butler, K. S. (2020) · Bioscience Reports · doi:10.1042/bsr20200127 · Cited by 192
“expression to the cells of interest (113, 114).”
BackgroundGene therapy and gene correction: targets, progress, and challenges for treating human diseases
Cring, M. R., & Sheffield, V. C. (2022) · Gene Therapy · doi:10.1038/s41434-020-00197-8 · Cited by 158
Metadata
- Authors
- Rodrigues, G. A., Shalaev, E., Karami, T. K., Cunningham, J., Slater, N. K. H., & Rivers, H. M.
- Affiliations
- Allergan (United States) (US)
- University of Cambridge (GB)
- Corresponding author
- Rivers, Hongwen M.
- Venue
- Pharmaceutical Research
- Published
- 2018-12-27
- Volume
- 36
- Issue
- 2
- Pages
- 29-29
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- PMC
- PMC6308217
- OpenAlex
- W2908402311
- Cited by
- 213
- References
- 122
- Citations by year
- 2026: 8 · 2025: 26 · 2024: 30 · 2023: 34 · 2022: 23 · 2021: 37 · 2020: 32 · 2019: 23
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Pharmaceutical Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- Allergan
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus vectors, ocular gene therapy, voretigene neparvovec, RPE65, inherited retinal disease, vector selection, target selection, chemistry, manufacturing and controls, pharmaceutical product development, FDA approval
- MeSH terms
- Drug Development, Dependovirus, Animals, Drug Compounding, Genetic Vectors, Humans, Macular Degeneration, Retinal Diseases, Genetic Therapy, Gene Transfer Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.